Sandra and Edward Meyer Cancer Center

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. 

Investigators from Weill Cornell Medicine have discovered a defense mechanism that protects skin cancer cells from oxidative stress and helps them spread.

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center. 

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, Memorial Sloan Kettering, and other institutions.

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine.

A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.

Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Institute investigators and their colleagues.

A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.

Researchers at Weill Cornell Medicine have used artificial intelligence to identify drug targets based on mapping regulatory networks in patient tumors.

Weill Cornell Medicine has received a five-year, $12.4 million grant from the National Cancer Institute, part of the National Institutes of Health, for an extensive program of basic and translational research on the biology of diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma.

A multi-institutional clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.

Two Medicaid policies can interact to increase oncology clinical trial enrollment among Black and Hispanic patients, according to a new study by investigators at Weill Cornell Medicine, the University of Pennsylvania, and Medidata AI.

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research.

An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.

Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute in Boston have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a rapidly growing field that uses high-resolution digital images created from tissue samples to help diagnose disease and guide treatment.

Researchers at Weill Cornell Medicine with an international team have used liver biopsies to identify cellular and molecular markers that can potentially be used to predict whether and when pancreatic cancer will spread to an individual’s liver or to another organ.

Before a cell commits fully to the process of dividing itself into two new cells, it may ensure the appropriateness of its commitment by staying for many hours—sometimes more than a day—in a reversible intermediate state, according to a discovery by researchers at Weill Cornell Medicine. 

Weill Cornell Medicine received a $1.5 million grant from the U.S. Department of Defense Prostate Cancer Research Program to develop new approaches for predicting the spread of cancer to the bone in men with prostate cancer at early stages of the disease.